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Mysterious Regulator
in Myocardial Fibrosis
and Circulating miR-29a
as a BiomarkerMyocardial ﬁbrosis is characterized by pathological
modiﬁcation of myocardium, in which cardiomyo-
cytes undergo apoptosis and the heart tissue is
replaced by ﬁbroblasts; this phenomenon is usually
referred to as cardiac remodeling. However, the
pathogenesis of myocardial ﬁbrosis is still unclear
despite advances in our understanding of the
ischemic process.
MicroRNAs (miRs), small endogenous noncoding
RNAs, have a well-documented role in the regulation
of the cardiovascular system. miRs such as miR-29
and miR-21 have been shown to have a role in the
genesis of myocardial ﬁbrosis.
Roncarati et al. (1) measured a set of miRs in the
plasma of patients with hypertrophic cardiomyopathy
to understand which miRs can be regarded as bio-
markers of this disease. Only miR-29a levels were
found to correlate with cardiac ﬁbrosis, along with
several miRs related to cardiac hypertrophy. This
discovery is signiﬁcant in that it may help deﬁne
patients who may develop ﬁbrosis. However, it is
important to know where miR-29a comes from and
what types of cells, cardiomyocytes or ﬁbroblasts,
secrete it. Previous studies have shown the opposite
effect of miR-29 in different types of cells (2–5).
On one hand, miR-29 can promote cardiomyocyte
apoptosis via down-regulation of antiapoptosis
genes, such as Bcl-2, CDC42, and Tcl-1 (2–4); on the
other hand, miR-29 can protect against ﬁbrosis
through inhibition of collagens released from ex-
tracellular matrix (5). Because the majority of
cell types change from cardiomyocyte to myoﬁ-
broblast phenotype during progression of cardiac
remodeling, it is reasonable to hypothesize that
up-regulation of miR-29a in the plasma of these pa-
tients is mainly due to cardiomyocyte apoptosis and
not secretion from ﬁbroblasts. It is also possible that
the up-regulation of miR-29a in plasma reﬂects thebody’s attempt to express more ﬁbrosis-protective
mediators to prevent adverse cardiac remodeling.
Cardiac remodeling is a complicated process that
involves a number of molecular and pathological
alterations (5). A simple measurement of miRs at one
time point may not be enough to deﬁne molecular
changes. Identiﬁcation of miR-29a (and other miRs) in
different cell types and at different time points is
necessary before recognizing it as a biomarker for
cardiac remodeling.Yao Dai, MD
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Regulator in Myocardial Fibrosis and
Circulating miR-29a as a BiomarkerWe thank Dr. Dai and colleagues for their interest in
our paper (1). As their letter suggests, it is possible that
microRNA (miR)-29 is secreted by more than one cell
type. However, our intention was not to address this
question, which has been partly done and should be
tackled further in other settings and with appropriate
technologies (tissue-speciﬁc knockout mice, trans-
genic mice, and so on); we simply found a signiﬁcant
correlation between a few circulating miRs, in par-
ticular miR-29a, and the degree of cardiac ﬁbrosis
in patients with hypertrophic cardiomyopathy.
We therefore agree with the concept expressed in
the letter by Dr. Dai and colleagues that miR-29s are
expressed in many cell types, where it probably plays
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2182a critical regulatory role. As stated in the letter, this
miR family has been found to be an important player
not only in ﬁbroblasts and ﬁbrosis but also in re-
gulating the functions of macrophages and other
inﬂammatory and immune cell types. It is worth
noting that inﬂammation precedes or accompanies
ﬁbrosis. Fibrosis and inﬂammation are therefore 2
highly correlated phenomena. It is also possible, even
though not yet proven, that miR-29s play a role in
cardiomyocytes. As previously noted, more experi-
mental studies need to address these important
questions. The published data today show that a
nonselective, ubiquitous knockout of miR-29s affects
cardiac ﬁbrosis in mice. To determine which cell
type is responsible for this phenomenon, miR-29 cell-
speciﬁc knockout approaches are needed.*Gianluigi Condorelli, MD, PhD
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